J&J's Darzalex Faspro Wins First-Ever FDA Approval for Smoldering Multiple Myeloma
SHERIDAN, WYOMING - November 10, 2025 - Johnson & Johnson has secured a major regulatory milestone for its oncology portfolio, with the U.S. Food and Drug Administration granting approval for Darzalex Faspro in patients with high-risk smoldering multiple myeloma. The expansion marks the first-ever therapy authorized for this pre-malignant stage of the disease, reinforcing J&J's leadership in hematologic oncology and enabling earlier clinical intervention to delay disease progression.
A Landmark Step Toward Early Intervention in Myeloma
Darzalex Faspro's new indication targets adults with high-risk smoldering multiple myeloma-patients statistically more likely to develop active disease within two years of diagnosis. By offering the first approved option at this pre-symptomatic stage, J&J is advancing a proactive "disease interception" approach that could reshape treatment timelines for oncologists and hematology practices.